Stocks and Investing Stocks and Investing
Mon, August 1, 2022

Matthew Harrison Maintained (ABBV) at Buy with Decreased Target to $188 on, Aug 1st, 2022


Published on 2024-10-27 22:20:25 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "AbbVie Inc." (ABBV) at Buy with Decreased Target from $191 to $188 on, Aug 1st, 2022.

Matthew has made no other calls on ABBV in the last 4 months.



There are 9 other peers that have a rating on ABBV. Out of the 9 peers that are also analyzing ABBV, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Luisa Hector of "Berenberg" Reiterated at Hold and Held Target at $135 on, Friday, July 15th, 2022
  • Geoff Meacham of "B of A Securities" Reiterated at Hold and Held Target at $156 on, Tuesday, June 21st, 2022
  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $140 on, Tuesday, April 12th, 2022


These are the ratings of the 6 analyists that currently disagree with Matthew


  • Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $160 on, Friday, July 29th, 2022
  • Terence Flynn of "Morgan Stanley" Maintained at Buy with Increased Target to $191 on, Friday, July 8th, 2022
  • David Risinger of "SVB Leerink" Initiated at Sell and Held Target at $140 on, Monday, May 23rd, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $200 on, Monday, May 2nd, 2022
  • Tim Anderson of "Wolfe Research" Maintained at Buy with Decreased Target to $170 on, Sunday, May 1st, 2022
  • Steve Scala of "TD Cowen" Maintained at Buy with Increased Target to $180 on, Thursday, April 14th, 2022
Contributing Sources